Treatment for hepatitis C virus infection in adults
Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R
Record ID 32013000770
English
Authors' objectives:
This report systematically reviews the comparative benefits and harms of current antiviral treatment regimens for chronic hepatitis C virus (HCV) infection in treatment-naïve adults.
Authors' recommendations:
Although there is no direct evidence on the comparative effects of current antiviral regimens on long-term clinical outcomes, SVR rates are substantially higher in patients with HCV genotype 1 infection who receive triple therapy with pegylated interferon (alfa-2a or alfa-2b), ribavirin, and boceprevir or telaprevir compared with dual therapy with pegylated interferon plus ribavirin. Achieving an SVR following antiviral therapy appears to be associated with decreased risk of all-cause mortality compared with no SVR, although estimates are susceptible to residual confounding.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://effectivehealthcare.ahrq.gov/ehc/products/286/1298/CER76_HepatitisC-Treatment_FinalReport_20121022.pdf
URL for additional information:
http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1298
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Hepatitis C
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.